Unicycive Therapeutics, Inc.
UNCYHealthcare|Biotechnology|US
$3.55
+0.07 (+2.01%)
DCF Value
$1.81
Tangible Book / Share
$1.98
Cash / Share
$2.28
Financials
Financial Snapshot
Market Cap
$97.2M
Enterprise Value
$53.7M
Revenue (TTM)
$0.00
Net Income (TTM)
-$35.2M
Cash & Investments
$61.4M
Net Cash
$60.8M
Free Cash Flow (TTM)
-$27.8M
Operating CF (TTM)
-$27.8M
Debt/Equity
0.01
Cash Runway & Burn Rate
Cash on Hand
$61.4M
Quarterly Burn
$7.0M
Monthly Burn
$2.3M
Est. Runway
~8.8 quarters
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $25.0K | $15.0K | $0.00 | $16.6M | $455.0K | $9.7M | $26.1M | $41.3M | $61.4M | |
| Operating Cash Flow | -$775.0K | -$1.2M | -$1.5M | -$5.8M | -$15.7M | -$18.3M | -$28.6M | -$31.3M | -$27.8M | |
| Free Cash Flow | -$775.0K | -$1.2M | -$1.5M | -$5.8M | -$15.7M | -$18.3M | -$28.6M | -$31.3M | -$27.8M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | -$29.0K | -$2.0K | -$12.0K | -$72.0K | -$24.0K | -$9.0K | |
| Financing Cash Flow | $800.0K | $1.2M | $1.4M | $22.4M | -$471.0K | $27.5M | $45.1M | $46.5M | $66.9M |
R&D Spending
R&D (TTM)
$9.6M
R&D Intensity
—
R&D Growth vs Prior
+5.4%
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $951.0K | $675.0K | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $344.0K | $795.0K | $1.0M | $6.1M | $12.4M | $12.9M | $20.0M | $9.1M | $9.6M | |
| R&D % of Revenue | — | — | — | — | 1307.7% | 1911.4% | — | — | — | |
| SG&A | $608.0K | $1.2M | $1.0M | $2.9M | $6.6M | $8.5M | $12.1M | $20.4M | $23.5M |
Income Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $951.0K | $675.0K | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $572.0K | $211.0K | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $951.0K | $675.0K | $0.00 | -$572.0K | -$211.0K | |
| R&D | $344.0K | $795.0K | $1.0M | $6.1M | $12.4M | $12.9M | $20.0M | $9.1M | $9.6M | |
| SG&A | $608.0K | $1.2M | $1.0M | $2.9M | $6.6M | $8.5M | $12.1M | $20.4M | $23.5M | |
| Operating Income | -$952.0K | -$2.0M | -$2.0M | -$9.0M | -$18.1M | -$20.8M | -$32.1M | -$29.5M | -$33.1M | |
| Interest Expense | $0.00 | $139.0K | $244.0K | $628.0K | $6.0K | $82.0K | $71.0K | $71.0K | $42.0K | |
| Pretax Income | -$1.1M | -$2.2M | -$2.3M | -$10.0M | -$18.1M | -$30.5M | -$36.7M | -$26.6M | -$35.2M | |
| Net Income | -$1.1M | -$2.3M | -$2.5M | -$10.0M | -$18.1M | -$30.5M | -$36.7M | -$26.6M | -$35.2M | |
| EPS (Diluted) | -0.73 | -1.42 | -1.48 | -6.68 | -11.99 | -12.80 | -5.65 | -1.67 | -1.67 | |
| EBITDA | $0.00 | -$63.0K | $0.00 | -$9.4M | -$17.9M | -$30.2M | -$36.2M | -$25.9M | -$34.5M | |
| Shares Out. (M) | 1.52 | 1.52 | 1.52 | 1.50 | 1.51 | 2.45 | 6.70 | 15.89 | 26.92 |
Balance Sheet
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $25.0K | $15.0K | $0.00 | $16.6M | $455.0K | $9.7M | $26.1M | $29.2M | $44.2M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $12.1M | $17.2M | |
| Total Current Assets | $29.0K | $19.0K | $204.0K | $18.4M | $2.6M | $13.4M | $30.9M | $49.0M | $71.3M | |
| Total Assets | $29.0K | $19.0K | $204.0K | $18.7M | $2.8M | $14.2M | $31.7M | $49.1M | $72.0M | |
| Total Current Liabilities | $1.2M | $903.0K | $2.9M | $2.1M | $3.3M | $17.5M | $24.1M | $18.9M | $18.7M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $1.2M | $903.0K | $2.9M | $2.3M | $3.3M | $18.0M | $24.2M | $18.9M | $18.8M | |
| Stockholders' Equity | -$1.2M | -$884.0K | -$2.7M | $16.5M | -$466.0K | -$3.8M | $7.4M | $30.2M | $53.3M | |
| Retained Earnings | -$1.5M | -$3.7M | -$5.9M | -$15.9M | -$34.0M | -$64.5M | -$101.3M | -$127.8M | -$142.4M |
Cash Flow Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$775.0K | -$1.2M | -$1.5M | -$5.8M | -$15.7M | -$18.3M | -$28.6M | -$31.3M | -$27.8M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | -$29.0K | -$2.0K | -$12.0K | -$72.0K | -$24.0K | -$9.0K | |
| Free Cash Flow | -$775.0K | -$1.2M | -$1.5M | -$5.8M | -$15.7M | -$18.3M | -$28.6M | -$31.3M | -$27.8M | |
| Investing Cash Flow | $0.00 | $0.00 | $0.00 | -$29.0K | -$2.0K | -$12.0K | -$72.0K | -$12.1M | -$17.3M | |
| Financing Cash Flow | $800.0K | $1.2M | $1.4M | $22.4M | -$471.0K | $27.5M | $45.1M | $46.5M | $66.9M | |
| Issuance of Stock | $250.0K | $1.2M | $141.0K | $22.3M | $11.0K | $0.00 | $683.0K | $48.1M | $67.6M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $1.4M | -$15.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $24.0K | $232.0K | $966.0K | $1.0M | $1.8M | $2.4M | $2.6M | $4.4M | |
| Net Change in Cash | $25.0K | -$10.0K | -$15.0K | $16.6M | -$16.1M | $9.2M | $16.4M | $3.1M | $21.9M |
Dilution Tracker
Shares outstanding grew 942.0% over 5 years — significant dilution
Shares Outstanding
27M
5-Year Share Growth
+942.0%
Stock Issuance (TTM)
$67.6M
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 1.52 | 1.52 | 1.52 | 1.50 | 1.51 | 2.45 | 6.70 | 15.89 | 26.92 | |
| Change vs Prior % | — | 0.0% | 0.0% | -1.6% | 0.4% | 63.0% | 173.0% | 137.2% | 69.4% | |
| Stock Issuance | $250.0K | $1.2M | $141.0K | $22.3M | $11.0K | $0.00 | $683.0K | $48.1M | $67.6M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $24.0K | $232.0K | $966.0K | $1.0M | $1.8M | $2.4M | $2.6M | $4.4M |
Margins & Profitability
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | — | 100.0% | 100.0% | — | — | — | |
| Operating Margin % | — | — | — | — | -1898.2% | -3077.6% | — | — | — | |
| Net Margin % | — | — | — | — | -1898.8% | -4525.0% | — | — | — | |
| EBITDA Margin % | — | — | — | — | -1881.3% | -4470.8% | — | — | — | |
| FCF Margin % | — | — | — | — | -1646.0% | -2710.4% | — | — | — | |
| ROE % | 92.9% | 260.6% | 93.9% | -60.8% | 3875.1% | 801.9% | -494.3% | -87.9% | -88.8% | |
| ROA % | -3862.1% | -12126.3% | -1229.4% | -53.4% | -640.8% | -215.2% | -116.0% | -54.0% | -48.9% | |
| ROIC % | 598.7% | 463.0% | -4697.7% | -53.4% | 6812.1% | 692.9% | -391.5% | -97.1% | -61.4% | |
| R&D / Revenue % | — | — | — | — | 1307.7% | 1911.4% | — | — | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -29.0% | -100.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -29.0% | -100.0% | 0.0% | |
| Operating Income | 0.0% | -106.2% | -2.9% | -344.4% | -101.1% | -15.1% | -54.6% | 8.1% | |
| Net Income | 0.0% | -105.7% | -8.9% | -299.4% | -80.3% | -69.1% | -20.2% | 27.7% | |
| EPS (Diluted) | 0.0% | -94.5% | -4.2% | -351.4% | -79.5% | -6.8% | 55.9% | 70.4% | |
| Operating Cash Flow | 0.0% | -51.7% | -24.1% | -295.3% | -171.4% | -16.8% | -56.3% | -9.6% | |
| Free Cash Flow | 0.0% | -51.7% | -24.1% | -297.3% | -170.1% | -16.9% | -56.6% | -9.4% | |
| R&D Expense | 0.0% | 131.1% | 27.7% | 499.0% | 104.5% | 3.7% | 55.1% | -54.4% | |
| SG&A Expense | 0.0% | 92.1% | -14.0% | 188.3% | 126.7% | 30.2% | 41.6% | 68.5% | |
| Total Assets | 0.0% | -34.5% | 973.7% | 9088.2% | -85.0% | 403.6% | 123.2% | 55.2% | |
| Book Value / Share | 0.0% | 26.7% | -202.1% | 727.4% | -102.8% | -401.5% | 171.5% | 71.3% | |
| Debt | 0.0% | -56.1% | 446.5% | -86.7% | -40.0% | 303.5% | -4.7% | -74.3% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | -1.6% | 0.4% | 63.0% | 173.0% | 137.2% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B1.79
10Y Low / Med / High1.87 / 3.04 / 7.16
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$1.81
Tangible Book / Share
$1.98
Net Current Assets / Share
$1.92
Graham Net-Net
$1.59
Cash / Share
$2.28
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -68.49 | -35.21 | -33.78 | -3.08 | -0.45 | -0.68 | -1.41 | -3.46 | -2.12 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 8.55 | 31.56 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -63.21 | -86.24 | -28.54 | 1.87 | -17.45 | -5.59 | 7.16 | 3.04 | 1.79 | |
| EV/EBITDA | 0.00 | -1217.13 | 0.00 | -1.56 | -0.44 | -0.41 | -0.77 | -2.42 | -1.56 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 8.28 | 18.39 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-0.39
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $1.5M | $131.4M | $612.3M |
| Net Income | -$17.6M | $51.5M | $169.4M |
| EPS | $-1.25 | $1.41 | $8.72 |
| # Analysts (EPS) | 7 | 7 | 7 |